Managed Access Program
Lonafarnib Managed Access Program Launched!
We are thrilled to announce that, as of August 2019, the lonafarnib Managed Access Program (MAP) is now up and running. PRF and lonafarnib manufacturer, Eiger BioPharmaceuticals, have worked together to create this program. The MAP allows eligible children and young adults with Progeria to obtain the drug lonafarnib through their local physicians in countries that allow the MAP to be offered.
Please click below for the PDF details in various languages.